Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration

Journal of Bacteriology

Volumn 190, Issue 8, 2008, Pages 2981-2986

  Sohaskey, Charles D ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRATE; NITRATE REDUCTASE; NITRIC OXIDE; PHENOTHIAZINE DERIVATIVE; THIORIDAZINE;

ANAEROBIC GROWTH; ARTICLE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIUM CULTURE; CONCENTRATION (PARAMETERS); ENZYME MECHANISM; HYPOXIA; MICROBIAL RESPIRATION; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATION; OXYGEN SUPPLY; PRIORITY JOURNAL; TUBERCULOSIS;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; ETHANOL; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; NITRATE REDUCTASE; NITRATES; NITRITES; OXYGEN; STEM CELLS; THIORIDAZINE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 41949097208     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.01857-07     Document Type: Article

References (32)

1. Amaral, L., J. E. Kristiansen, L. S. Abebe, and W. Millett. 1996. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38:1049-1053.
2. Amaral, L., M. Martins, and M. Viveiros. 2007. Phenothiazines as anti-multidrug resistant tubercular agents. Infect. Dis. Drug Targets 7:257-265.
3. Amaral, L., J. E. Kristiansen, M. Viveiros, and J. Atouguia. 2001. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47:505-511.
4. Bettencourt, M. V., S. Bosne-David, and L. Amaral. 2000. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 16:69-71.
5. Boon, C., and T. Dick. 2002. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J. Bacteriol. 184:6760-6767.
6. Boshoff, H. I. M., and C. E. I. Barry. 2005. Tuberculosis - metabolism and respiration in the absence of growth. Nat. Rev. 3:70-80.
7. Boshoff, H. I. M., T. G. Myers, B. R. Copp, M. R. McNeil, M. A. Wilson, and C. E. I. Barry. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism. J. Biol. Chem. 279:40174-40184.
8. Chan, E. D., J. Chan, and N. W. Schluger. 2001. What is the role of nitric oxide in murine and human host defense against tuberculosis? Am. J. Respir. Cell Mol. Biol. 25:606-612.
9. Dye, C., S. Cheele, P. Olin, P. Ikram, and M. C. Aviglioen. 1999. Global burden of tuberculosis. JAMA 282:677-686.
10. Fenhalls, G., L. Stevens, L. Moses, J. Bezuidenhout, J. C. Betts, P. van Helden, P. T. Lukey, and K. Duncan. 2002. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect. Immun. 70:6330-6338.
11. Fritz, C., S. Maass, A. Kreft, and F.-C. Bange. 2002. Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Infect. Immun. 70:286-291.
12. Goh, K. S., N. Rastogi, M. Berchel, R. C. Huard, and C. Sola. 2005. Molecular evolutionary history of tubercle bacilli assessed by study of the polymorphic nucleotide within the nitrate reductase (narGHJI) operon promoter. J. Clin. Microbiol. 43:4010-4014.
13. Haapanen, J. H., I. Kass, G. Gensini, and G. Middlebrook. 1959. Studies on the gaseous content of tuberculous cavities. Am. Rev. Respir. Dis. 80:1-5.
14. James, P. E., O. Y. Grinberg, G. Michaels, and H. M. Swartz. 1995. Intraphagosomal oxygen in stimulated macrophages. J. Cell. Physiol. 163:241-247.
15. Martins, M., Z. Schelz, A. Martins, J. Molnar, G. Hajõs, Z. Riedl, M. Viveiros, I. Yalcin, E. Aki-Sener, and L. Amaral. 2007. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 10:1016-1019.
16. Nathan, C. 2002. Inducible nitric oxide synthase in the tuberculous human lung. Am. J. Respir. Crit. Care Med. 166:130-131.
17. Ordway, D., M. Viveiros, C. Leandro, R. Betterncourt, J. Almeida, M. Martins, J. E. Kristiansen, J. Molnar, and L. Amaral. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922.
18. Rachman, H., M. Strong, T. Ulrichs, L. Grode, J. Schuchhardt, H. Mollenkopf, G. A. Kosmiadi, D. Eisenberg, and S. H. E. Kaufmann. 2006. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect. Immun. 74:1233-1242.
19. Sherman, D. R., M. Voskuil, D. Schnappinger, R. Liao, M. I. Harrell, and G. K. Schoolnik. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin. Proc. Natl. Acad. Sci. USA 98:7534-7539.
20. Shi, L., C. D. Sohaskey, B. D. Kana, S. Dawes, R. J. North, V. Mizrahi, and M. L. Gennaro. 2005. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl. Acad. Sci. USA 102:15529- 15534.
21. Sohaskey, C. D. 2005. Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide. Microbiology 151:3803-3810.
22. Sohaskey, C. D., and L. G. Wayne. 2003. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J. Bacteriol. 185:7247-7256.
23. Thanacoody, H. K. R. 2007. Thioridazine: resurrection as an antimicrobial agent. Br. J. Clin. Pharmacol. 64:566-571.
24. Viveiros, M., and L. Amaral. 2001. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17:225-228.
25. Voskuil, M. I., D. Schnappinger, M. I. Harrell, K. C. Visconti, G. M. Dolganov, D. R. Sherman, and G. K. Schoolnik. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis persistence program. J. Exp. Med. 198:705-713.
26. Wade, M. M., and Y. Zhang. 2004. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J. Med. Microbiol. 53:769-773.
27. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
28. Wayne, L. G., and L. G. Hayes. 1998. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuber. Lung Dis. 79:127-132.
29. Wayne, L. G., and C. D. Sohaskey. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163.
30. Weinstein, E. A., T. Yano, L.-S. Li, D. Avarbock, A. Avarbock, D. Helm, A. A. McColm, K. Duncan, J. T. Lonsdale, and H. Rubin. 2005. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. USA 102:4548-4553.
31. Yano, T., L.-S. Li, E. Weinstein, J.-S. Teh, and H. Rubin. 2006. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281:11456-11463.
32. Zhang, Y., M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.